Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sabine Imhof-Jung"'
Autor:
Hans Peter Grimm, Vanessa Schumacher, Martin Schäfer, Sabine Imhof-Jung, Per-Ola Freskgård, Kevin Brady, Carsten Hofmann, Petra Rüger, Tilman Schlothauer, Ulrich Göpfert, Maximilian Hartl, Sylvia Rottach, Adrian Zwick, Shanon Seger, Rachel Neff, Jens Niewoehner, Niels Janssen
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThere are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the b
Externí odkaz:
https://doaj.org/article/1e3d18094e0b44a99ca3a99a2f9d46b6
Autor:
Guy J. Georges, Stefan Dengl, Alexander Bujotzek, Friederike Hesse, Jens A.A. Fischer, Achim Gärtner, Jörg Benz, Matthias E. Lauer, Philippe Ringler, Henning Stahlberg, Friederike Plath, Ulrich Brinkmann, Sabine Imhof-Jung
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss , Pp 1210-1220 (2020)
The careful design of the antibody architecture is becoming more and more important, especially when the purpose is agonism. We present the design of a novel antibody format that is able to promote receptor dimerization and induce signal transduction
Externí odkaz:
https://doaj.org/article/e63a7374d4ac4858b91e6da04a61a06c
Autor:
Cornelia Fischer, Michael W. Munks, Ann B. Hill, Richard A. Kroczek, Stefan Bissinger, Verena Brand, Martina Schmittnaegel, Sabine Imhof-Jung, Eike Hoffmann, Frank Herting, Christian Klein, Hendrik Knoetgen
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Simulating a viral infection in tumor cells is an attractive concept to eliminate tumor cells. We previously reported the molecular design and the in vitro potency of recombinant monoclonal antibodies fused to a virus-derived peptide MHC class I comp
Externí odkaz:
https://doaj.org/article/906184eb45f44cc1b0adba53618c102c
Autor:
Frieder Bauss, Martin Lechmann, Ben-Fillippo Krippendorff, Roland Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan O. Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner
Publikováno v:
Molecular Oncology, Vol 10, Iss 8, Pp 1317-1329 (2016)
Mesothelin overexpression in lung adenocarcinomas correlates with the presence of activating KRAS mutations and poor prognosis. Hence SS1P, a mesothelin‐targeted immunotoxin, could offer valuable treatment options for these patients, but its use in
Externí odkaz:
https://doaj.org/article/016854fb9481433287e7d8721af2694e
Autor:
Sebastian Fenn, Christian B Schiller, Julia J Griese, Harald Duerr, Sabine Imhof-Jung, Christian Gassner, Joerg Moelleken, Joerg Thomas Regula, Wolfgang Schaefer, Markus Thomas, Christian Klein, Karl-Peter Hopfner, Hubert Kettenberger
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61953 (2013)
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action. There is a wide variety of design
Externí odkaz:
https://doaj.org/article/d35ff357608844489f263722db7ce824
Autor:
Ira Pastan, Gerhard Niederfellner, Sabine Imhof-Jung, Xiu-fen Liu, Emily Mason-Osann, Kevin Hollevoet
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and new therapies are needed. RG7787 is a novel low-immunogenic antimesothelin recombinant immunotoxin (RIT), engineered to overcome the limitations of SS1P, a RIT now in clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d295334101bfde3d1966f3c94de7e23
https://doi.org/10.1158/1535-7163.c.6536662.v1
https://doi.org/10.1158/1535-7163.c.6536662.v1
Autor:
Hendrik Knoetgen, Christian Klein, Guy Georges, Georg Drabner, Cornelia Fischer, Sabine Imhof-Jung, Eike Hoffmann, Martina Schmittnaegel
Protein sequences of all recombinant fusion proteins described in the manuscript
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63a123c1d81be8204513558fbd9e6046
https://doi.org/10.1158/1535-7163.22503856.v1
https://doi.org/10.1158/1535-7163.22503856.v1
Autor:
Ira Pastan, Gerhard Niederfellner, Sabine Imhof-Jung, Xiu-fen Liu, Emily Mason-Osann, Kevin Hollevoet
PDF - 60K, Toxicity studies for RG7787 were performed in athymic nude mice. General health and weight was evaluated during therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dead6f50e14e809449aac83e1fe08fc
https://doi.org/10.1158/1535-7163.22501018.v1
https://doi.org/10.1158/1535-7163.22501018.v1
Autor:
Ira Pastan, Gerhard Niederfellner, Sabine Imhof-Jung, Xiu-fen Liu, Emily Mason-Osann, Kevin Hollevoet
PDF - 207K, A: Untreated KLM-1 tumors stain strongly for mesothelin. B-D: Mesothelin expression is not affected by treatment with RG7787, paclitaxel or both. IHC was done by Histoserv, Inc. according to a standard protocol. Representative pictures (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::398f49eea6479c4aa772e39cb4eb33c6
https://doi.org/10.1158/1535-7163.22501024
https://doi.org/10.1158/1535-7163.22501024
Autor:
Ira Pastan, Gerhard Niederfellner, Sabine Imhof-Jung, Xiu-fen Liu, Emily Mason-Osann, Kevin Hollevoet
PDF - 261K, Supplementary methods related to the IHC protocol and supplementary figure legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f729e9f9900913955c97f2bee005588
https://doi.org/10.1158/1535-7163.22501021
https://doi.org/10.1158/1535-7163.22501021